Crowley Wealth Management Inc. Acquires New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Crowley Wealth Management Inc. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,250 shares of the biopharmaceutical company's stock, valued at approximately $294,000.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after purchasing an additional 98,303 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $10,283,000. AXQ Capital LP purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $387,000. American Century Companies Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.7% in the 4th quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company's stock worth $377,443,000 after buying an additional 11,291 shares during the last quarter. Finally, Quantbot Technologies LP raised its position in shares of Alnylam Pharmaceuticals by 678.4% during the 4th quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company's stock valued at $374,000 after buying an additional 1,384 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Wells Fargo & Company increased their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday, March 21st. HC Wainwright boosted their target price on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty have issued a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $312.30.

Remove Ads

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 over the last ninety days. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ:ALNY traded up $1.81 on Thursday, hitting $271.02. The company had a trading volume of 984,089 shares, compared to its average volume of 811,079. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm's 50-day simple moving average is $259.42 and its two-hundred day simple moving average is $260.39. The firm has a market capitalization of $35.09 billion, a price-to-earnings ratio of -124.89 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.